The Breakthrough: SickKids Leads Global Update to Paediatric Clinical Trial Reporting

Researchers at The Hospital for Sick Children (SickKids) in Toronto have unveiled groundbreaking guidelines that promise to transform how paediatric randomized controlled trials (RCTs) are documented and shared worldwide. On February 24, 2026, the SPIRIT-Children and Adolescents (SPIRIT-C) 2026 and CONSORT-Children and Adolescents (CONSORT-C) 2026 extensions were co-published in prestigious journals including The BMJ, JAMA Pediatrics, and The Lancet Child & Adolescent Health. These standards build on the foundational SPIRIT 2025 and CONSORT 2025 frameworks, adding paediatric-specific items to address the unique needs of trials involving newborns, infants, children, and adolescents aged 0 to 19 years.

Developed by the SickKids EnRICH (Enhancing the Quality and Transparency of Health Research in Child Health) team, these guidelines emphasize transparency, reproducibility, and relevance. They incorporate perspectives from youth aged 10-24 and family caregivers, marking a first in reporting guideline development. This child-centred approach ensures protocols and reports reflect real-world paediatric care realities, from age-appropriate dosing to minimizing pain and distress during procedures.

In Canada, where children and youth with medical complexity represent less than 1% of the paediatric population but account for 37% of hospital stays, robust clinical trial standards are crucial for advancing evidence-based treatments. SickKids' contributions position Canadian institutions at the forefront of global child health research.

Understanding SPIRIT and CONSORT: Foundations for Trial Excellence

Before diving into the extensions, it's essential to grasp the originals. SPIRIT, or Standard Protocol Items: Recommendations for Interventional Trials, provides a checklist for RCT protocols, ensuring all critical elements—like objectives, eligibility, interventions, and outcomes—are clearly outlined before a study begins. CONSORT, the Consolidated Standards of Reporting Trials, guides the reporting of completed trial results, promoting complete and transparent accounts to allow replication and informed decision-making.

These tools have revolutionized adult trials, reducing research waste and enhancing trust in findings. However, paediatric trials present distinct challenges: developmental changes affect dosing, outcomes must be age-appropriate (e.g., growth metrics over blood pressure), and ethical considerations like assent from capable children add layers of complexity. Historically, adult-centric guidelines led to incomplete paediatric reporting, hindering extrapolation and application.

SPIRIT-C 2026 adds 17 new items to SPIRIT 2025, while CONSORT-C 2026 introduces 13 to CONSORT 2025. Four SPIRIT-C items and one CONSORT-C item were youth-generated, with several endorsed by young advisors—a pioneering inclusion that prioritizes end-user needs.

The Rigorous Development Journey at SickKids EnRICH

Led by Senior Project Manager Ami Baba and Senior Scientist Dr. Martin Offringa, both affiliated with the University of Toronto's Department of Pediatrics, the EnRICH team orchestrated a multi-year effort starting in 2023. Registered with the EQUATOR Network since 2014 (updated 2023-2024), the process followed best practices: systematic literature reviews identified gaps, generating candidate items from prior 2015 extensions and updated searches.

• Delphi Survey: 266 international experts (including 10 caregivers and 4 youth) across three rounds refined items to 23, achieving high consensus rates.
• Consensus Meeting: 31 of 38 invitees (including caregivers) voted on inclusions, harmonizing with CONSORT-C.
• Youth Engagement: Pan-Canadian youth (13-19) and international workshops with 42 young people (10-21) from Canada, UK, France, Scotland, Spain shaped items.
• Pilot Testing: 22 testers refined wording; 11 more for CONSORT-C.
• Writing and Review: 27 authors crafted explanation papers with exemplars.

Funded by CIHR and others, this collaboration involved 50 authors from Canada (U Toronto, UBC, U Alberta, U Ottawa) and globally, underscoring Canadian leadership.SickKids Announcement

SPIRIT-C 2026: Revolutionizing Paediatric Trial Protocols

SPIRIT-C targets the planning phase, embedding 17 items into SPIRIT 2025. Key additions include:

• Item 1a.1 (Title): Specify paediatric population (e.g., "3-6 years intractable epilepsy").
• Item 9a.1-9a.3 (Background): Prevalence/incidence by age, extrapolation from adults/other kids, child-specific research question.
• Item 13.1 (Eligibility): Adaptations for inclusion (e.g., interpreters, audio materials).
• Item 14a.1: Age groups/developmental stages justified.
• Item 15a.1-15a.3 (Interventions): Dose/formulation by weight/age/BSA, adaptations (e.g., paediatric VR), support persons (e.g., parents administering meds).
• Item 16.1 (Outcomes): Validity/reliability/feasibility for paediatrics, reporter (child/parent).
• Item 17.1-17.2 (Harms): Pain/distress mitigation, risk reduction.
• Item 20.1-20.2 (Recruitment): Daily life impact, recognition (e.g., vouchers).
• Item 32a.1: Age-appropriate consent materials.
• Item 34.1: Long-term follow-up plans.

These ensure protocols account for growth spurts, assent processes, and family roles, harmonized with TIDieR-C for interventions.JAMA Pediatrics SPIRIT-C

For academics drafting protocols, these checklists streamline ethics approvals and funding pitches. Explore clinical research jobs at Canadian universities to contribute.

CONSORT-C 2026: Transparent Reporting of Paediatric Results

CONSORT-C focuses on post-trial reports, adding 13 items like youth-generated 13.2 (intervention fidelity). Highlights:

• Item 6.2-6.3: Age-stratified baselines, developmental changes.
• Item 13.1-13.2: Fidelity assessments, adaptations implemented.
• Item 15.1: Age-specific outcomes.
• Item 25.1: Ancillary analyses by age.
• Item 29.1: Interpretation considering development.

This ensures results are interpretable across ages, vital for meta-analyses.JAMA Pediatrics CONSORT-C

University researchers can leverage these for publications; check academic CV tips.

Addressing Key Challenges in Canadian Paediatric Trials

Canada faces hurdles in paediatric research: fewer trials due to smaller populations, ethical complexities (e.g., assent), inter-provincial barriers, and limited age-appropriate endpoints. Only 12% of drugs have paediatric labelling despite off-label use being common. Funding shortages and regulatory gaps exacerbate issues.

SPIRIT-C/CONSORT-C mitigate by mandating details on extrapolation, harms, and long-term follow-up, aiding multi-site Canadian networks like those at U Toronto or UBC. They align with CIHR priorities, potentially boosting grants.

Step-by-step: (1) Identify gaps in adult data; (2) Adapt interventions developmentally; (3) Engage families early; (4) Report stratified results. This reduces waste, estimated at 50% in trials globally.

Youth and Family Voices: A Paradigm Shift

Unlike prior guidelines, these integrate direct input: pan-Canadian youth advisors co-designed workshops; 42 international youth contributed items like recognition for participation and daily life impacts. Caregivers advised on consent and ancillary care.

"Young people shared what matters most for health decisions," notes patient partner Maureen Smith. This fosters trust, uptake, and relevance.

For med students, this models patient-oriented research; rate profs leading such work on Rate My Professor.

Implications for Higher Education and Research Careers in Canada

SickKids-UofT collaboration highlights opportunities in paediatric methodology. Universities like U Toronto (Temerty Faculty) train via programs emphasizing these standards, preparing for faculty positions or clinical research roles.

Benefits:

• Training: Integrates into med/grad curricula.
• Careers: Demand for trialists rises; see postdoc advice.
• Funding: CIHR/SPOR networks prioritize transparent trials.
• Global Impact: Canadian lead influences regulators like Health Canada.

Explore Canada university jobs in child health.

Real-World Examples and Case Studies

Exemplars from protocols: VR for IV pain in kids details goggles, age adaptations; curcumin drops specify BSA dosing. Reports must stratify by age, fidelity checks.

Canadian case: Hypothetical SickKids trial on epilepsy stimulation reports youth-endorsed stress mitigation, boosting replicability.

Photo by Markus Winkler on Unsplash

Future Outlook: Adoption and Evolution

SickKids plans uptake tracking; journals, funders, ethics boards urged to mandate. Future: LMIC input, non-RCT extensions. In Canada, strengthens networks like IMINDS, advancing precision child health.

"Clearer evidence means better care," says Offringa. For researchers, visit higher ed jobs, university jobs, rate profs, career advice.